Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland
Timo Purmonen,1 Kari Puolakka,2 Dinesh Mishra,3 Praveen Gunda,3 Janne Martikainen4 1Novartis Finland Oy, Espoo, Finland; 2South Karelia Central Hospital, Lappeenranta, Finland; 3Novartis Product Lifecycle Services-NBS, Novartis Healthcare Private Limited, Hyderabad, India; 4School of Pharmacy, Unive...
Saved in:
Main Authors: | Purmonen T (Author), Puolakka K (Author), Mishra D (Author), Gunda P (Author), Martikainen J (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2019-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Secukinumab for ankylosing spondylitis and psoriatic arthritis
by: Lubrano E, et al.
Published: (2016) -
Effectiveness of secukinumab for overlapping hidradenitis suppurativa and ankylosing spondylitis
by: Mariam AlAfeefi, et al.
Published: (2024) -
Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis
by: Elena Conesa-Nicolás, et al.
Published: (2021) -
Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative
by: Colombo GL, et al.
Published: (2018) -
Short-Term Efficacy and Safety of Secukinumab for Ankylosing Spondylitis: A Systematic Review and Meta-Analysis of RCTs
by: Yu Zhou, et al.
Published: (2020)